Value of intraocular pressure for assessment of ocular safety of intranasal steroids

doi:10.16150/j.1671-2870.2019.04.016

Abstract

Abstract:

Objective: Many side effects including elevation of intraocular pressure (IOP) due to long-term use of intranasal steroids were reported, especially with the first generation intranasal steroids, yet the second generation intranasal steroids were believed only having a minimal impact on IOP because of low bioavailability. The object of this study was to assess the value of IOP for assessing the ocular safety of two intranasal steroids (the first generation and the second generation) for treatment of 12-week period. Methods: Fifty two allergic rhinitis patients were divided randomly into two groups using either the first or second generation intranasal steroids for 12 weeks, respectively. IOPs were measured before treatment and after the 3rd, 6th, 9th, and 12th weeks of treatment. The IOPs of the two groups were compared. Results: The IOP of the first-generation intranasal steroids at 3, 6 and 9 weeks after treatment were not statistically different from those before treatment, while the IOP at 12 weeks after treatment were statistically different from those before treatment. Meanwhile, there were no statistically significant differences between the IOP at various stages of treatment and that before treatment with the use of second generation intranasal steroids. Conclusions: For patient with long standing use of nasal steroids, IOP could be considered as an important index for assessing the ocular safety.

Key words: Intraocular pressure, Intranasal steroids, Allergic rhinitis

CLC Number:

R541.7

WU Jichang, HE Gangxun, SHI Zhihong, CHEN Yan. Value of intraocular pressure for assessment of ocular safety of intranasal steroids[J]. Journal of Diagnostics Concepts & Practice, 2019, 18(04): 466-469.

Figures/Tables 2

References 18

[1]	LaForce C, Journeay GE, Miller SD, et al. Ocular safety of fluticasone furoate nasal spray in patients with perennial allergic rhinitis: a 2-year study[J]. Ann Allergy Asthma Immunol, 2013, 111(1):45-50. doi: 10.1016/j.anai.2013.04.013 URL
[2]	Liu A, Manche EE. Bilateral posterior subcapsular cataracts associated with long-term intranasal steroid use[J]. J Cataract Refract Surg, 2011, 37(8):1555-1558. doi: 10.1016/j.jcrs.2011.05.020 URL
[3]	Opatowsky I, Feldman RM, Gross R, et al. Intraocular pressure elevation associated with inhalation and nasal corticosteroids[J]. Ophthalmology, 1995, 102(2):177-179. pmid: 7862403
[4]	葛坚. 眼科学[M]. 北京: 人民卫生出版社, 2002:50.
[5]	Kersey JP, Broadway DC. Corticosteroid-induced glaucoma: a review of the literature[J]. Eye (Lond), 2006, 20(4):407-416. pmid: 15877093
[6]	Bross-Soriano D, Hanenberg-Milver C, Schimelmitz-Idi J, et al. Effects of three nasal topical steroids in the intraocular pressure compartment[J]. Otolaryngol Head Neck Surg, 2004, 130(2):187-191. doi: 10.1016/j.otohns.2003.09.020 URL
[7]	Bergmann J, Witmer MT, Slonim CB. The relationship of intranasal steroids to intraocular pressure[J]. Curr Allergy Asthma Rep, 2009, 9(4):311-315. doi: 10.1007/s11882-009-0044-z URL
[8]	Garbe E, LeLorier J, Boivin JF, et al. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma[J]. JAMA, 1997, 277(9):722-727. doi: 10.1001/jama.1997.03540330044033 URL
[9]	Oztürk F, Yücetürk AV, Kurt E, et al. Evaluation of intraocular pressure and cataract formation following the long-term use of nasal corticosteroids[J]. Ear Nose Throat J, 1998, 77(10):846-848,850-851. doi: 10.1177/014556139807701012 URL
[10]	Bui CM, Chen H, Shyr Y, et al. Discontinuing nasal steroids might lower intraocular pressure in glaucoma[J]. J Allergy Clin Immunol, 2005, 116(5):1042-1047. doi: 10.1016/j.jaci.2005.07.031 URL
[11]	Spiliotopoulos C, Mastronikolis NS, Petropoulos IK, et al. The effect of nasal steroid administration on intraocular pressure[J]. Ear Nose Throat J, 2007, 86(7):394-395. doi: 10.1177/014556130708600714 URL
[12]	Bousquet J, van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma[J]. J Allergy Clin Immunol, 2001, 108(5 Suppl):S147-S334.
[13]	Clark AF, Wilson K, McCartney MD, et al. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells[J]. Invest Ophthalmol Vis Sci, 1994, 35(1):281-294.
[14]	Benninger MS, Ahmad N, Marple BF. The safety of intranasal steroids[J]. Otolaryngol Head Neck Surg, 2003, 129(6):739-750. doi: 10.1016/j.otohns.2003.10.001 URL
[15]	Yuen D, Buys YM, Jin YP, et al. Effect of beclomethasone nasal spray on intraocular pressure in ocular hypertension or controlled glaucoma[J]. J Glaucoma, 2013, 22(2):84-87. doi: 10.1097/IJG.0b013e3182254811 URL
[16]	Dreyer EB. Inhaled steroid use and glaucoma[J]. N Engl J Med, 1993, 329(24):1822.
[17]	Man LX, Farhood Z, Luong A, et al. The effect of intranasal fluticasone propionate irrigations on salivary cortisol, intraocular pressure, and posterior subcapsular cataracts in postsurgical chronic rhinosinusitis patients[J]. Int Forum Allergy Rhinol, 2013, 3(12):953-957. doi: 10.1002/alr.21228 URL
[18]	Spiliotopoulos C, Mastronikolis NS, Petropoulos IK, et al. The effect of nasal steroid administration on intraocular pressure[J]. Ear Nose Throat J, 2007, 86(7):394-395. doi: 10.1177/014556130708600714 URL

分组	平均年龄（岁）	性别（男/女）
第一代鼻用激素组	52.49±19.35	13/9
第二代鼻用激素组	49.98±14.38	16/14
P值	P>0.05	P>0.05
t/χ²值	1.267	1.582

时间段	第一代鼻用激素组						第二代鼻用激素组
时间段	左眼	t值	P值	右眼	t值	P值	左眼	t值	P值	右眼	t值	P值
治疗前	13.97±2.18			12.66±2.35			13.86±1.54			14.36±1.65
3周	13.89±1.94	1.822	0.66	13.94±3.72	1.238	0.51	13.84±1.61	1.086	0.78	14.33±1.62	1.102	0.67
6周	15.52±3.98	2.446	0.23	15.28±4.89	3.568	0.37	13.92±1.58	1.192	0.70	14.32±1.61	1.125	0.65
9周	17.18±4.57	5.743	0.14	16.45±6.12	6.994	0.08	13.99±1.86	1.236	0.63	14.41±1.72	1.196	0.52
12周	20.88±6.51	10.165	0.03	19.44±5.81	12.831	0.02	13.87±2.66	1.093	0.94	14.38±2.56	1.089	0.78